LATEST
外 Waitan Ludi Policy Terminal China industrial-policy monitor · updated 2026-11-10
view asAnalystMonitorPolicymakerBusinessLegal
← Documents · Graph

吉林省人民政府公报

吉政办发〔2023〕35号

Country-interest evidence · pilot

Trade inferences use UN Comtrade, with China as reporter. Country connections indicate potential trade relevance, not measured harm, firm-level exposure or legal applicability. Inward measures concern exporters to China; competition with Chinese exports in third markets is not assessed.

Inspect implementing jurisdictions and partner evidence · 60 relationships

Implementing jurisdiction: China · intervention 68648

Argentina: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 86,326,233

Australia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 399,570,761

Austria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 515,027,182

Belgium: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 811,226,075

Bulgaria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 15,542,440

Brazil: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 32,852,382

Barbados: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 25,717,430

Canada: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 401,897,458

Switzerland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 3,367,152,363

Costa Rica: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 485,339,666

Cyprus: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 3,074,778

Czech Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 77,734,313

Germany: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 10,854,571,849

Denmark: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 1,034,323,091

Dominican Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 94,740,759

Egypt, Arab Rep.: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 2,326,564

Spain: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 618,939,280

Estonia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 1,876,491

Finland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 162,913,316

France: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 3,433,422,103

United Kingdom: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 1,741,115,527

Greece: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 258,085,497

Hong Kong, China: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 537,001,440

Hungary: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 100,395,949

Indonesia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 9,209,339

India: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 207,161,833

Ireland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 6,965,702,672

Iceland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 4,385,848

Israel: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 494,443,527

Italy: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 2,586,457,410

Japan: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 3,216,532,157

Korea, Rep.: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 834,722,801

Lithuania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 2,352,093

Mexico: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 2,178,940,134

Malta: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 1,660,942

Malaysia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 272,730,047

Netherlands: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 1,258,706,383

Norway: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 64,746,652

New Zealand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 104,276,990

Pakistan: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 11,814,401

Philippines: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 11,418,194

Poland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 111,746,768

Romania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 12,026,802

Russian Federation: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 7,021,267

Singapore: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 678,843,564

Slovak Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 3,202,070

Slovenia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 35,097,631

Sweden: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 1,450,256,646

Thailand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 133,054,258

Turkey: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 47,217,622

Chinese Taipei: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 376,246,942

Ukraine: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 2,109,213

Uruguay: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 25,423,673

United States: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 11,958,602,627

Vietnam: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 359,918,905

South Africa: Trade-based inference; exporters to China; summed product trade > USD 1m; 2022 trade; broad sector headings; computed, not analyst-reviewed · intervention 68649 · recorded trade USD 19,107,905

Implementing jurisdiction: China · intervention 68649

Implementing jurisdiction: China · intervention 68650

Implementing jurisdiction: China · intervention 68651

Assessment states
  • Trade-based partners recorded
  • No sector coded; treated as horizontal by the source calculation (not independently confirmed)
  • No sector coded; treated as horizontal by the source calculation (not independently confirmed)
  • No sector coded; treated as horizontal by the source calculation (not independently confirmed)

Measures

Capital grant
Provincial · origin: Chinese firms or production in China · locality: Local firms · CPC 352; 481 · Keyword screen (unreviewed)
Implemented by China (subnational) · affects 56 partners (inferred from trade data, 2022 trade): United States, Germany, Ireland, France, Switzerland, Japan …
Stated rationale
  • Regional development · document title or opening · unreviewed 为深入贯彻落实党的二十大精神和习近平总书记在新时代推动东北全面振兴座谈会上的重要讲话精神
在省科技发展计划中设立吉林省生物药和高端医疗器械重大科技专项，5年内每年通过省级科技创新专项资金（以下简称专项资金）投入额度不低于1000万元。
Supports production in a place, so favours that place by rule.
Interest subsidy
Provincial · origin: Chinese firms or production in China · locality: Local firms · Keyword screen (unreviewed)
Implemented by China (subnational) · no affected jurisdictions listed: no sector named, so treated as horizontal: no affected jurisdictions
Stated rationale
  • Regional development · document title or opening · unreviewed 为深入贯彻落实党的二十大精神和习近平总书记在新时代推动东北全面振兴座谈会上的重要讲话精神
对新建的投资5000万元以上、取得预期经济效益的重大产业项目，按照其固定资产实际发生贷款额和贷款利率，给予专项资金最高不超过100万元贴息补助。
Supports production in a place, so favours that place by rule.
Local production condition
Provincial · origin: Chinese firms or production in China · locality: Local firms · Keyword screen (unreviewed)
Implemented by China (subnational) · no affected jurisdictions listed: no sector named, so treated as horizontal: no affected jurisdictions
Stated rationale
  • Regional development · document title or opening · unreviewed 为深入贯彻落实党的二十大精神和习近平总书记在新时代推动东北全面振兴座谈会上的重要讲话精神
对本省生产进入国家集中带量采购中标的品种，按照不高于中标量销售额的10%，单个品种给予专项资金最高不超过200万元奖补。
Tax relief
Provincial · origin: Chinese firms or production in China · locality: Local firms · Keyword screen (unreviewed)
Implemented by China (subnational) · no affected jurisdictions listed: no sector named, so treated as horizontal: no affected jurisdictions
Stated rationale
  • Regional development · document title or opening · unreviewed 为深入贯彻落实党的二十大精神和习近平总书记在新时代推动东北全面振兴座谈会上的重要讲话精神
优化提升税费服务，深入开展增值税留抵退税、高新技术企业所得税优惠、小微企业税收优惠、企业研发费用加计扣除、技术转让所得减免、技术成果投资入股等税收优惠政策宣传辅导。
Supports production in a place, so favours that place by rule.

Asymmetric provisions

Local production requirement (本地生产)
Disadvantages: imports firms from other regions · Keyword screen (unreviewed)
对本省生产进入国家集中带量采购中标的品种，按照不高于中标量销售额的10%，单个品种给予专项资金最高不超过200万元奖补。
Local production requirement (本地生产)
Disadvantages: imports firms from other regions · Keyword screen (unreviewed)
对本省生产的产品，在符合相关条件下，可按药械采购相关规定在吉林省挂网采购。
Local production requirement (本地生产)
Disadvantages: imports firms from other regions · Keyword screen (unreviewed)
对在本省生产的首次在美国食品药品管理局、欧洲药品管理局等国际权威机构注册或认证的，同时在国际市场上市销售的品种，按年销售收入的20%，单个品种给予专项资金一次性最高不超过200万元奖补。

Full text

吉林省人民政府办公厅印发 关于打造吉林省生物医药与高端医疗器械 产业新赛道实施方案的通知 吉政办发〔2023〕35号 各市（州）人民政府，长白山管委会，各县（市）人民政府，省政府各厅委办、各直属机构，驻吉中直有关部门、单位： 《关于打造吉林省生物医药与高端医疗器械产业新赛道的实施方案》已经省政府同意，现印发给你们，请认真抓好贯彻落实。 吉林省人民政府办公厅 2023年12月2日 关于打造吉林省生物医药与高端医疗器械 产业新赛道的实施方案 为深入贯彻落实党的二十大精神和习近平总书记在新时代推动东北全面振兴座谈会上的重要讲话精神，全面落实省委、省政府关于医药强省建设重大部署，按照新技术催生新产品、新业态、新规模、新增长点的思路，打造生物医药与高端医疗器械产业新赛道，聚力培育发展新动能新优势，结合我省实际，制定本方案。 一、主要目标 到2025年，吉林省生物医药与高端医疗器械产业力争实现总产值500亿元。开发新产品50个，扶持重大产业项目50个，培育重点企业50户，打造特色园区15个。产业发展环境持续优化，创新能力稳步提高，经营主体量质齐升，核心竞争力显著增强。 到2030年，吉林省生物医药与高端医疗器械产业力争实现总产值1000亿元。生物医药产业创新能力进入国家第一方阵，医疗器械产业实现高速高质发展，形成具有引领性发展、颠覆性创新、爆发式增长的新赛道。 二、重点任务 （一）聚焦产业高端，对标国际领先产品，抢占生物医药产业新高地。 1.疫苗领域。 （1）创新疫苗产品开发。重点开发疱疹mRNA疫苗、流感mRNA疫苗、重组带状疱疹疫苗、重组呼吸道合胞病毒疫苗、阿尔茨海默症疫苗、肿瘤疫苗等新型疫苗，推动疫苗产品国际化。 （2）新型佐剂及复合佐剂开发。重点开展疫苗纳米佐剂、黏膜佐剂等新型佐剂及复合佐剂生产关键技术研究。 （3）疫苗重大项目建设。重点推动百克生物疫苗产业园、卓谊生物医药产业园等重大产业项目建设，打造国内领先的疫苗产业新高地。 2.基因工程药物领域。 （1）基因工程药物创新产品开发。重点开发具有自主知识产权的重组白蛋白注射液、超长效生长激素注射液、超长效胰岛素注射液、重组人促卵泡激素Fc融合蛋白注射液、德谷胰岛素利拉鲁肽注射液等创新产品。 （2）基因工程药物关键技术研究。重点开展工业化大规模高密度发酵技术、高纯度重组蛋白药物分离纯化技术、高载量及高通量亲和层析技术、多种融合蛋白分子设计或偶联途径的长效化技术研究。 （3）基因工程药物重大项目建设。重点推动安睿特生物重组人白蛋白生产基地、东宝生物医药产业园、四环医药惠升胰岛素项目、金赛药业产业园等重大产业项目建设，以工程化、清单化推动项目落地见效。 3.抗体药物领域。 （1）抗体药物创新产品开发。重点开展重组全人源抗RANKL单克隆抗体注射液、依洛尤单抗注射液等创新产品研发，加快填补我省抗体药物产品市场空白。 （2）抗体药物关键技术研究。重点开展应用磁珠和稀土纳米颗粒的拉曼传感关键技术研究，突破抗体亲和力无法进行高通量筛选的技术难题。开展细胞培养和蛋白质纯化关键技术研究，解决重组全人源化单克隆抗体国产化的难题。 4.细胞治疗领域。 （1）细胞制剂产品开发。重点开展干细胞、免疫细胞药物药效学、生产工艺、检验及质量标准、安全性评价等相关研究。加快细胞治疗领域核心装备、试剂及材料的国产化研发。 （2）细胞制备技术研究。重点开展间充质干细胞、T淋巴细胞、NK细胞（自然杀伤）、树突状细胞等细胞规模化制备及质量控制等关键技术研究，开展干细胞、免疫细胞国家标准、地方标准的研究与制定，提升产业的规范化水平。 （3）推进细胞研究项目备案。充分发挥临床医学研究机构作用，与企业开展备案项目合作。重点推进应用干细胞外泌体治疗缺血性和出血性脑损伤的临床前研究、干细胞制剂临床研究等。 5.合成生物学领域。 （1）合成生物学药物开发。重点布局合成生物技术在制药领域的应用，利用合成生物学方法设计和构建新的疫苗、抗体药物和基因药物。 （2）合成生物学关键技术研究。重点开展基因合成、基因组编辑、高通量筛选、工艺集成和规模化生产、产品提纯等关键技术研究。 （二）突破技术瓶颈，加速要素国产替代，跑出医疗器械产业新速度。 1.体外诊断领域。 （1）智能分子诊断高端设备开发。重点开发单细胞测序仪、数字PCR自动化一体机、AI全光谱流式细胞分析仪等高端设备，以及微流控芯片、高性能滤光片、激光器等关键器件或试剂，实现国产化替代。 （2）生化与免疫临床检验高端设备开发。重点开发全自动智能一体化生化检验设备、高速全自动化学发光免疫分析仪等高端设备，以及校准品、复合质控品、高性能磁球、发光标记材料等关键原材料和检测试剂盒，打破国外产品垄断局面。 （3）即时检验检测设备开发。重点开发生物芯片与配套设备、蛋白质传感器设备与配套试剂、免疫发光检测设备与检测试剂、辅助生殖诊断设备及配套试剂等，实现自主创新。 2.智能光电诊疗领域。 （1）智能高清内窥镜和手术机器人开发。重点开发AI导航超高清3D内窥镜、智能高清多通道椎间孔镜及配套设备、AI胸腹腔微创手术机器人以及智能骨折复位机器人，打破国外产品垄断。 （2）智能光学诊疗高端设备开发。重点开发激光器关键器件、激光治疗智能化系统、高峰值功率强激光治疗设备、中波紫外光治疗设备。 （3）智能康复及可穿戴设备开发。重点开发数字化、便捷化、精细化、智能化康复训练和生活辅助康复机器人，数据云端化、诊断远程化的智能可穿戴式设备。 （4）智能医学影像及病理检验系统开发。重点开发CT、MRI等影像智能辅助诊断与评估系统、病理切片染色体人工智能图像分析系统，提高诊断效率。 3.生物医用材料领域。 （1）高性能生物修复材料开发。重点开发软骨修复、软组织固定、骨折内固定等骨修复和固定材料，高性能生物降解聚酯、非生物降解聚合物等神经修复材料。 （2）高性能医用植入物材料开发。重点开发人工韧带、人工神经等系列运动医学新产品，新型水胶体敷料、止血材料等功能性敷料产品。 （3）高性能荧光标记材料开发。重点开发高性能全光谱流式细胞分析标记荧光素、多色荧光微球等新产品，实现国产化替代。 4.医美产品领域。 （1）医学整形材料开发。重点开发新型医美注射填充材料、整形植入材料等系列医学整形新产品，建立新型生物医用材料和创新产品检测标准。 （2）医美创新产品开发。重点开发透明质酸钠凝胶类、重组人纤连蛋白类等医美创新产品，推动以延吉医美、中韩（长春）国际合作示范区为代表的高端医美行业与国外的交流合作。 5.制药装备与检测仪器领域。 （1）智能制药装备开发。重点开发提取分离、制药用水、药品包装等智能化制药成套装备（设备）。 （2）智能药品检测装备开发。重点开发智能化、信息化药品检测技术及配套装备（设备），光谱、质谱分析仪等高端药品检测仪器。 三、推进举措 （一）营造产业发展新环境。强化顶层设计，编制生物药和高端医疗器械产业发展研究报告，指导产业发展。在省科技发展计划中设立吉林省生物药和高端医疗器械重大科技专项，5年内每年通过省级科技创新专项资金（以下简称专项资金）投入额度不低于1000万元。对本省生产进入国家集中带量采购中标的品种，按照不高于中标量销售额的10%，单个品种给予专项资金最高不超过200万元奖补。对本省生产的产品，在符合相关条件下，可按药械采购相关规定在吉林省挂网采购。 （二）激发产业发展新活力。对由企业自主研发的生物药在开展临床试验、申报注册、转化生产等不同阶段，分别给予专项资金最高不超过200万元奖补；对开展临床试验的第三类医疗器械、首次注册且在我省转化生产的第三类医疗器械或国家创新医疗器械给予专项资金一次性最高不超过100万元奖励；对在本省生产的首次在美国食品药品管理局、欧洲药品管理局等国际权威机构注册或认证的，同时在国际市场上市销售的品种，按年销售收入的20%，单个品种给予专项资金一次性最高不超过200万元奖补。 （三）培育产业发展新力量。对营业收入首次超10亿元和以10亿元为一档倍数递增且纳入生物药和医疗器械领域规模以上统计范围的工业企业，每一档给予专项资金最高不超过200万元奖补。实施吉林省科技企业R&D经费投入引导计划，实行“免申即享”政策，对符合条件的省内生物药和医疗器械领域中小微企业R&D投入增量和大型企业R&D投入增量与存量，给予专项资金最高不超过100万元补助。 （四）打造产业发展新集群。推动长春药谷等集群建设，加快圣博玛超高性能医疗器械、吉原水凝胶先进功能材料等重大项目建设。对新建的投资5000万元以上、取得预期经济效益的重大产业项目，按照其固定资产实际发生贷款额和贷款利率，给予专项资金最高不超过100万元贴息补助。对通过招商引资与兼并重组的企业在我省实施的技术提升改造与产品优化升级项目，按其新购科研仪器设备实际投资额的20%，给予专项资金最高不超过100万元奖补。 （五）搭建产业服务新载体。加强药物非临床安全性评价机构（GLP）、药品临床试验平台（GCP）、医药研发外包（CRO）、医药定制研发生产外包（CDMO）、医药生产外包（CMO）、医药销售外包（CSO）、药品检测平台（包含细胞药物）等服务平台建设，增强公共服务能力，谋划组建概念验证中心。对新组建且实际运行的服务平台，给予专项资金一次性最高不超过300万元的奖补。对年度考核评价结果为合格，且年度促成技术合同成交额500万元（含）以上的省内技术转移示范机构，按照不超过促成的经认定的技术合同成交额的2.5%，给予专项资金最高不超过30万元的补助。组建吉林省疫苗、基因工程药物、细胞治疗、mRNA技术、医疗器械等科技创新联盟（联合体），解决产业共性关键问题。 （六）完善产业发展新链条。对首次纳入生物药和医疗器械规模以上统计直报的工业企业，在首个统计年度实现产值和营业收入均同比增长10％以上的，给予专项资金一次性最高不超过50万元奖补。对新入规入统的企业连续3年保持在规上统计的，且每个年度产值、营业收入和税收均实现10％以上增速的，给予专项资金一次性最高不超过50万元奖补。对通过网上支付工具结算、年成交额首次超过1亿元的流通企业，给予专项资金一次性最高不超过50万元奖补。 （七）构筑产业人才新洼地。切实落实《关于激发人才活力支持人才创新创业的若干政策措施（3.0版）》（吉发〔2022〕18号）扶持政策，制定医药产业吸引集聚高端人才的政策措施。对领办创办企业、转化自主创新成果、推动商业模式创新、带动产业发展、产生较大经济社会效益的中青年科技创业人才（团队），给予专项资金一次性最高不超过30万元补助。通过组织“创客中国”吉林省中小企业创新创业大赛、中国创新创业大赛（吉林赛区）等活动，对优秀团队项目给予立项。 （八）拓展产业合作新渠道。吸引全球500强企业来吉投资布局，加速吉商企业回归，积极引进先进技术与战略投资者，承接产业转移。对在我省新设立企业总部或地区总部、研发中心、生产基地，税收及统计关系落在本省内，注册资本金在1亿元以上且年营业收入超5000万元的，给予专项资金一次性最高不超过100万元奖补。对域外引进的、在我省转化生产且年销售收入超2000万元的重大品种，单个品种给予专项资金一次性最高不超过100万元奖补。 （九）发挥金融资源新效能。发挥政府产业基金的投资引导作用，吸引社会资本围绕我省医药健康产业发起设立子基金。采取科技专项与投资基金、银行信贷组合的方式，助力生物药与医疗器械领域省级科技计划项目成果快速转化。对总部和主营业务均在吉林省的“腾飞类”拟上市企业培训库企业，并在主板、创业板、科创板及北交所成功上市的企业，以及在境外主要证券交易所（香港联交所主板、纽约证券交易所、纳斯达克证券交易所等）成功上市的企业，单户企业一次性或分阶段给予不超过1000万元奖补。 （十）增强服务保障新手段。各地区要结合实际，建立生物医药与医疗器械产业重大项目专家库、审议专班，以“一事一议”“一企一策”的方式依法依规给予政策支持和保障服务。优化提升税费服务，深入开展增值税留抵退税、高新技术企业所得税优惠、小微企业税收优惠、企业研发费用加计扣除、技术转让所得减免、技术成果投资入股等税收优惠政策宣传辅导。深化职能转变，推进投资审批便利化、药品审批高效化、器械审批优先化，提升对委托生产的药品上市许可持有人、接受委托的药品生产企业资质审批发放效率。